Patient characteristics
| Characteristic . | Autologous SCT in first remission (AUTO1, n = 50) . | Autologous SCT for relapsed / refractory MCL (AUTO2, n = 36) . | Nonmyeloablative allogeneic SCT (NST, n = 35) . |
|---|---|---|---|
| Median age, y (range) | 57 (38-73) | 59 (42-76) | 58 (43-68) |
| Male, n (%) | 44 (88) | 29 (81) | 27 (77) |
| Female, n (%) | 6 (12) | 7 (19) | 8 (23) |
| Median time from initial diagnosis, mo (range) | 7 (4-63) | 27 (5-84)* | 44 (11-119)† |
| Median no. of prior chemotherapy regimens (range) | 1 | 2 (2-4)* | 3 (1-10)† |
| Performance status ≥ 1, n (%) | 23 of 49 (47) | 15 of 31 (48) | 14 (40) |
| Stage 3 or 4, n (%) | 46 (92) | 33 (92) | 35 (100) |
| Prior B symptoms, n (%) | 14 (28) | 8 (22) | 6 (17) |
| Prior GI involvement, n (%) | 21 (42) | 12 (33) | 13 (37) |
| Prior blood involvement, n (%) | 8 (16) | 7 (19) | 8 (23) |
| Blastic morphology, n (%) | 5 (10) | 2 (6) | 1 (3) |
| β2-microglobulin ≥ 3 mg/L, n (%) | 12 of 44 (27) | 9 of 30 (30) | 7 (20) |
| Elevated LDH, n (%) | 7 (14) | 11 (31) | 10 (29) |
| PET/gallium positive before SCT | 1 (3) | 6 (29)* | 11 (33) |
| Bone marrow stem cell source, n (%) | 6 (12) | 5 (14) | 8 (23) |
| Chemosensitive disease at transplantation, n (%) | 50 (100) | 31 (86) | 29 (83) |
| CR/CRu at SCT, n (%) | 23 (46) | 25 (69) | 16 (46)† |
| PR at SCT, n (%) | 27 (54) | 6 (17) | 13 (37) |
| Refractory disease at SCT, n (%) | 0 (0) | 5 (14) | 6 (17) |
| MIPI low risk, n (%) | 16 (40) | 7 (47) | 9 (56) |
| MIPI intermediate risk, n (%) | 13 (33) | 2 (13) | 1 (6) |
| MIPI high risk, n (%) | 11 (28) | 6 (40) | 6 (38) |
| HSCT-CI < 3, n (%) | 28 (56) | 18 (50) | 21 (60) |
| HSCT-CI ≥ 3, n (%) | 22 (44) | 18 (50) | 14 (40) |
| Prior hyper-CVAD, n (%) | 29 (58) | 16 (44) | 1 (3)† |
| Prior R-hyper-CVAD, n (%) | 13 (26) | 6 (17) | 23 (66)† |
| Failed prior auto-SCT, n (%) | 0 (0) | 0 (0) | 6 (17)† |
| Rituximab during induction, and/or at transplantation, n (%) | 21 (42) | 19 (53) | 32 (91)† |
| Conditioning regimen, n (%) | |||
| Cy/TBI | 28 (56) | 15 (42) | |
| R-Cy/TBI | 9 (18) | 6 (17) | |
| R-BEAM | 11 (22) | 12 (33) | |
| Other | 2 (4) | 3 (8) | |
| PFA | 5 (14) | ||
| FCR | 30 (86) |
| Characteristic . | Autologous SCT in first remission (AUTO1, n = 50) . | Autologous SCT for relapsed / refractory MCL (AUTO2, n = 36) . | Nonmyeloablative allogeneic SCT (NST, n = 35) . |
|---|---|---|---|
| Median age, y (range) | 57 (38-73) | 59 (42-76) | 58 (43-68) |
| Male, n (%) | 44 (88) | 29 (81) | 27 (77) |
| Female, n (%) | 6 (12) | 7 (19) | 8 (23) |
| Median time from initial diagnosis, mo (range) | 7 (4-63) | 27 (5-84)* | 44 (11-119)† |
| Median no. of prior chemotherapy regimens (range) | 1 | 2 (2-4)* | 3 (1-10)† |
| Performance status ≥ 1, n (%) | 23 of 49 (47) | 15 of 31 (48) | 14 (40) |
| Stage 3 or 4, n (%) | 46 (92) | 33 (92) | 35 (100) |
| Prior B symptoms, n (%) | 14 (28) | 8 (22) | 6 (17) |
| Prior GI involvement, n (%) | 21 (42) | 12 (33) | 13 (37) |
| Prior blood involvement, n (%) | 8 (16) | 7 (19) | 8 (23) |
| Blastic morphology, n (%) | 5 (10) | 2 (6) | 1 (3) |
| β2-microglobulin ≥ 3 mg/L, n (%) | 12 of 44 (27) | 9 of 30 (30) | 7 (20) |
| Elevated LDH, n (%) | 7 (14) | 11 (31) | 10 (29) |
| PET/gallium positive before SCT | 1 (3) | 6 (29)* | 11 (33) |
| Bone marrow stem cell source, n (%) | 6 (12) | 5 (14) | 8 (23) |
| Chemosensitive disease at transplantation, n (%) | 50 (100) | 31 (86) | 29 (83) |
| CR/CRu at SCT, n (%) | 23 (46) | 25 (69) | 16 (46)† |
| PR at SCT, n (%) | 27 (54) | 6 (17) | 13 (37) |
| Refractory disease at SCT, n (%) | 0 (0) | 5 (14) | 6 (17) |
| MIPI low risk, n (%) | 16 (40) | 7 (47) | 9 (56) |
| MIPI intermediate risk, n (%) | 13 (33) | 2 (13) | 1 (6) |
| MIPI high risk, n (%) | 11 (28) | 6 (40) | 6 (38) |
| HSCT-CI < 3, n (%) | 28 (56) | 18 (50) | 21 (60) |
| HSCT-CI ≥ 3, n (%) | 22 (44) | 18 (50) | 14 (40) |
| Prior hyper-CVAD, n (%) | 29 (58) | 16 (44) | 1 (3)† |
| Prior R-hyper-CVAD, n (%) | 13 (26) | 6 (17) | 23 (66)† |
| Failed prior auto-SCT, n (%) | 0 (0) | 0 (0) | 6 (17)† |
| Rituximab during induction, and/or at transplantation, n (%) | 21 (42) | 19 (53) | 32 (91)† |
| Conditioning regimen, n (%) | |||
| Cy/TBI | 28 (56) | 15 (42) | |
| R-Cy/TBI | 9 (18) | 6 (17) | |
| R-BEAM | 11 (22) | 12 (33) | |
| Other | 2 (4) | 3 (8) | |
| PFA | 5 (14) | ||
| FCR | 30 (86) |
Patients were divided into those who underwent autologous stem cell transplantation (SCT) in first remission (AUTO1) or beyond first remission (AUTO2) and those who underwent nonmyeloablative SCT beyond first remission (NST).
GI indicates gastrointestinal; LDH, lactate dehydrogenase; CR, complete response; CRu, unconfirmed CR; PR, partial response; MIPI, Mantle Cell International Prognostic Index; and HSCT-CI, Hematopoietic Stem Cell Transplantation-Comorbidity Index.
P < .05 comparing AUTO1 and AUTO2.
P < .05 comparing AUTO2 and NST.